TNF-α antagonists for the treatment of juvenile-onset spondyloarthritides

Clinical and Experimental Rheumatology

Volumn 20, Issue 6 SUPPL. 28, 2002, Pages

  Horneff, Gerd ^a   Burgos Vargas, Rubén ^a  

^a Poliklinik fur Kinder/Jugendmedizin ^*  (Germany)

Author keywords

Etanercept; Infliximab; Juvenile arthritis; Juvenile onset spondyloarthritides

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTERITIS; ARTICLE; CASE REPORT; CASE STUDY; CLINICAL FEATURE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDICATION; ENTHESITIS; FUNCTIONAL DISEASE; HUMAN; IRIDOCYCLITIS; ONSET AGE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SACROILIITIS; SIDE EFFECT; SPONDYLITIS; SPONDYLOARTHROPATHY; SYNOVITIS; CHILD; DRUG ANTAGONISM; REVIEW; SPONDYLARTHRITIS;

AGE OF ONSET; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CHILD; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036401261     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. BURGOS-VARGAS R, PACHECO-TENA C, VÁZQUEZ-MELLADO J: Juvenile-onset spondyloarthropathies. Rheum Dis Clin North Am 1997; 23: 569-98.
2. BENNET PH, WOOD PHN: Population Studies of the Rheumatic Diseases, New York, Excerpta Medica, 1986: 456.
3. SOUTHWOOD TR, PETTY RE, MALLESON PN et al.: Psoriasis arthritis in childhood. Arthritis Rheum 1989; 32: 1007-13
4. PETTY RE, SOUTHWOOD TR, BAUM J et al.: Revision of the proposed criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998; 25: 1991-4.
5. BURGOS-VARGAS R, RUDWALEIT M, SIEPER J: The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. J Rheumatol 2002; 29: 869-74.
6. DOUGADOS M, VAN DER LINDEN S, JUHLIN R et al.: The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34: 1218-27.
7. BURGOS-VARGAS R, VÁZQUEZ-MELLADO J, PACHECO-TENA C, HERNÁNDEZ-GARDUÑO A, GOYCOCHEA-ROBLES MV: A 26-week randomized, double blind, placebo-controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis (in press).
8. GOMEZ KS, RAZA K, JONES SD et al.: Juvenile onset ankylosing spondylitis - more girls than we thought? J Rheumatol 1997; 24: 735-7.
9. BOWYER S, ROETTCHER P, members of the Pediatric Rheumatology Database Research Group: Pediatric rheumatology clinic populations in the United States: Results of a 3-year survey. J Rheumatol 1996; 23: 1968-74.
10. MALLESON PN, FUNG MY, ROSENBERG AM: The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996; 23: 1981-7.
11. SYMMONS DP, JONES M, OSBORNE J et al.: Juvenile rheumatoid arthritis in the United Kingdom: Data from the British Pediatric Rheumatology Group National diagnostic Register. J Rheumatol 1996; 23: 1975-80.
12. BURGOS-VARGAS R, VÁZQUEZ-MELLADO J: The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38: 835-44.
13. HUPPERTZ HI, TSCHAMMLER A, HORWITZ AE. SCHWAB KO: Intraarticular corticosteroids for chronic arthritis in children: Efficacy and effects on cartilage and growth. J Pediatr 1995; 127: 317-21.
14. BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-52.
15. VAN DEN BOSCH F, KRUITHOF E, BAETEN D, De KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428-33.
16. GORMAN JD, SACK KE, DAVIS JC: A randomized, double-blind, placebo-controlled trial of etanercept (Enbrel) in the treatment of ankylosing spondylitis. Arthritis Rheum 44 (Suppl. 1): 90S.
17. VAN DEN BOSCH F, KRUITHOF E, BAETEN D, De KEYSER F, MIELANTS H, VEYS EM: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2001; 44 (Suppl. 1): 153S.
18. KRUITHOF E, VAN DEN BOSCH F, BAETEN D, HERSSENS A, De KEYSER F, MIELANTS H, VEYS EM: Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: One year follow up. Ann Rheum Dis 2002; 61: 207-12.
19. BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002; 29: 118-22.
20. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
21. RUOF J, SANGHA O, STUCKI G: Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 1999; 58: 218-25.
22. REIFF A, HENRICKSON M: Prolonged efficacy of etanercept in refractory juvenile ankylosing spondylitis. Arthritis Rheum 2001; 44 (Suppl. 1): 292S.
23. LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-9.
24. SHORE A, ANSELL BM: Juvenile psoriatic arthritis - An analysis of 60 cases. J Pediatr 1982; 100: 529-35.
25. WILKENS RF, WILLIAMS HJ, WARD JR et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-81.
26. GUPTA AK, MATTESON EL, ELLIS CN et al.: Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 1989; 125: 507-10.
27. SPADARO A, TACCARI E, MOHTADI B, RICCIERI V, SENSI F, ZOPPINI A: Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol 1997;15: 609-14.
28. MEASE PJ, GOFFE BS, METZ J, VAN DER STOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
29. GIANNINI EH, RUPERTO N, RAVELI A, LOVELL DJ, FELSON DT, MARTINI A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
30. BREWERTON DA, JAMES DCO: The histo-compatibility antigen HLA-B27 and disease. Semin Arthritis Rheum 1975; 4: 191.
31. EVANS JMM, MCMAHON AD, MURRAY FE et al.: Non-steroidal anti-inflammatory drugs are associated with emergence admission for colitis due to inflammatory bowel disease. Gut 1997; 40: 619
32. VAN DEN BOSCH F, KRUITHOF E, DE VOS M, DE KEYSER F, MIELANTS H: Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-2.
33. EI-SHABRAWI Y, HERMANN J: Anti-TNFα therapy with infliximab in the treatment of acute anterior uveitis - A one year follow up. Arthritis Rheum 2001; 44 (Suppl. 1): 123S.
34. FRIES W, GIOFRE MR, CATANOSO M, LO GR: Treatment of acute uveitis associated with Crohn's disease and sacroiliitis with infliximab. J Rheumatol 2002; 29: 118-122.
35. REIFF A, TAKEI S, SADEGHI S, et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-5.
36. HONKANEN V, LAPPI M, KOSKINEN L, LINDAHL P, LAHDENNE P: Infliximab treatment in the refractory chronic uveitis of juvenile idiopathic arthritis (JIA). Arthritis Rheum 2001; 44 (Suppl. 1): 292S.
37. FLATO B, AASLAND A, VINJE O, FORRE O: Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998; 25: 366-375.
38. MINDEN K, KIESSLING U, LISTING J et al.: Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000; 27: 2256-63.
39. CALIN A, ELSWOOD S: The natural history of juvenile onset ankylosing spondylitis: 24 year retrospective case control study. Br J Rheumatol 1988; 27: 91-3.
40. GARCÍA-MORTEO O, MALDONADO-COCCO JA, SUÁREZ-ALMAZOR ME et al.: Ankylosing spondylitis of juvenile onset: Comparison with adult onset disease. Scand J Rheumatol 1983; 12: 246-8.
41. JIMÉNEZ J, MINTZ G: The onset, evolution and final stages of juvenile ankylosing spondylitis are different from those of adult onset ankylosing spondylitis. In DICK CA and CALABRO JJ: Ankylosing Spondylitis, 1st ed. Lancaster, MTP Press, 1987.
42. GROM AA, MURRAY KJ, LUYRINK L et al.: Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703-10.
43. MURRAY KJ, LUYRINK L, GROM AA et al.: Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis. J Rheumatol 1996; 23: 2116-24.
44. MURRAY KJ, GROM AA, THOMPSON SD, LIEUWEN D, PASSO MH, GLASS DN: Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 1998; 25: 1388-98.
45. HORNEFF G, FORSTER J, SEYBERTH W, MICHELS H: Empfehlungen der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie zur Therapie mit Etanercept (P75 TNF-Rezeptor- Immunglobulinfusionsprotein). Z Rheumatol 2001; 59: 0365-9.
46. BLOOM BJ: Development of diabetes mellitus during etanercept therapy in a child with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 2606-8.
47. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
48. SICOTTE NL, VOSKUHL RR: Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57: 1885-8.
49. WALLIS WJ, BURGE DJ, SABATH D, GARDINER M: Tuberculosis reports with etanercept (Enbrel) Therapy. Arthritis Rheum 2001; 44 (Suppl. 1): 78S.